NASDAQ:ABVC

Abvc Biopharma Stock Predictions

Healthcare > Biotechnology

Buy ABVC

*Your capital is at risk

$1.32

-0.0300 (-2.22%)

At Close: Jun 22, 2026

Currently predicting for Wed, 24 Jun 2026

ABVC Live board

Community Bull/Bear

Target Next close

Join the ABVC prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

ABVC Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For ABVC

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

ABVC Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT ABVC BIOPHARMA, INC.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity d...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
IDYA $28.98	18.12%	Jun 12
DHI $146.71	6.29%	Jun 10
PHM $118.49	6.02%	Jun 10
EAT $140.46	17.09%	Jun 05
E ETD $20.67	3.19%	Jun 05

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by